logo
Plus   Neg
Share
Email

Mylan, Pfizer Announce Epinephrine Auto-injector Settlement Agreement With Teva

Mylan Inc. (MYL) said Meridian Medical Technologies, a Pfizer (PFE) subsidiary, has entered into a settlement agreement with Teva (TEVA) that will resolve pending patent litigation related to its abbreviated new drug application for a generic epinephrine auto-injector.

According to the settlement terms, Teva may launch a generic epinephrine auto-injector covered by its ANDA on June 22, 2015 or earlier under certain circumstances, subject to receipt of approval from the U.S. Food and Drug Administration. Teva currently does not have tentative approval from the FDA for its epinephrine auto-injector product.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Thursday, Biogen Inc. (BIIB) raised its adjusted earnings guidance for the full-year 2021, but maintained revenue outlook. For fiscal 2021, the company raised its adjusted earnings guidance to a range of $17.50 to $19.00 per share from the... While reporting financial results for the first quarter on Thursday, electric utility American Electric Power Co., Inc. (AEP) reaffirmed its fiscal 2021 operating earnings guidance in the range of $4.55 to $4.75 per share. Including special items, estimated earnings would be between $4.56 and $4.76 per... Telecom major AT&T Inc. (T) reported Thursday significantly higher profit in its first quarter with growth in operating revenues that topped market estimates. Service revenues declined, offset by growth in equipment revenues. For the first quarter, net income attributable to common stock climbed 63.8 percent to $7.50 billion from last year's $4.58 billion.
Follow RTT